https://repub.eur.nl/pub/104203/REPUB_104203-OA.pdf

2017 HRS / EHRA / ECAS / APHRS / SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

https://www.onlinelibrary.wiley.com/doi/pdf/10.1016/j.joa.2016.07.002

An early repolarization (ER) pattern in the ECG, distinguished by J-point elevation, slurring of the terminal part of the QRS and ST-segment elevation has long been recognized and considered to be a benign electrocardiographic manifestation. Experimental studies conducted over a decade ago suggested that some cases of ER may be associated with malignant arrhythmias. Validation of this hypothesis was provided by recent studies demonstrating that an ER pattern in the inferior or inferolateral leads is associated with increased risk for life-threatening arrhythmias, termed ER syndrome (ERS). Because accentuated J waves characterize both Brugada syndrome (BS) and ERS, these syndromes have been grouped under the term "J wave syndromes". ERS and BS share similar ECG characteristics, clinical outcomes and risk factors, as well as a common arrhythmic platform related to amplification of Ito-mediated J waves. Although BS and ERS differ with respect to the magnitude and lead location of abnormal J wave manifestation, they can be considered to represent a continuous spectrum of phenotypic expression. Although most subjects exhibiting an ER pattern are at minimal to no risk, mounting evidence suggests that careful attention should be paid to subjects with "high risk" ER. The challenge ahead is to be able to identify those at risk for sudden cardiac death. Here I review the clinical and genetic aspects as well as the cellular and molecular mechanisms underlying the J wave syndromes. (Circ J 2012; 76: 1054-1065)

Genetic, molecular and cellular mechanisms underlying the J wave syndromes.

The review brings a comprehensive survey of recent developments and applications of high performance capillary and microchip electroseparation methods (zone electrophoresis, isotachophoresis, isoelectric focusing, affinity electrophoresis, electrokinetic chromatography, and electrochromatography) to analysis, micropreparation, purification, and physicochemical and biochemical characterization of peptides in the years 2013, 2014, and ca. up to the middle of 2015. Advances in the investigation of electromigration properties of peptides, in the methodology of their analysis, including sample preseparation, preconcentration and derivatization, adsorption suppression and EOF control, as well as in detection of peptides, are described. New developments in particular CE and CEC modes are presented and several types of their applications to peptide analysis are reported: conventional qualitative and quantitative analysis, determination in complex (bio)matrices, monitoring of chemical and enzymatical reactions and physical changes, amino acid, sequence, and chiral analysis, and peptide mapping of proteins. Some micropreparative peptide separations are shown and capabilities of CE and CEC techniques to provide important physicochemical characteristics of peptides are demonstrated.

Recent developments in capillary and microchip electroseparations of peptides (2017–mid 2019)

Brugada syndrome is an inherited cardiac disease and is associated with a peculiar pattern on the electrocardiogram and an increased risk of sudden death. Electrical storm is a malignant but rare phenomenon in symptomatic patients with Brugada syndrome. We describe a patient who presented with repetitive ICD discharges during two episodes of recurrent VF. After the initiation of isoproterenol infusion and oral quinidine, the ventricular tachyarrhythmias were successfully suppressed. (Neth Heart J 2007;15:151-4.)

Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally.

Background
The number of cardiac rhythm device implantations has been growing fast due to expanding indications and ageing of the population. Complications of implantation were rare in the trials. However, these involved small numbers and selected patients. Prospective real-life data are necessary to assess cardiac device implantation procedure-related risks.

/pdf/incidence-of-lead-dislodgement-malfunction-and-perforation-425w7fkj15.pdf

Incidence of lead dislodgement, malfunction and perforation during the first year following device implantation

Many important differences in the presentation and clinical course of cardiac arrhythmias are present between men and women that should be accounted for in clinical practice. In this paper, we review published data on gender differences in cardiac excitable properties, supraventricular tachycardias, ventricular tachycardias, sudden cardiac death, and the utilisation of implantable defibrillators and cardiac resynchronisation therapy. Women have a higher heart rate at rest, and a longer QT interval than men. They further have a narrower QRS complex and lower QRS voltages on the 12-lead ECG with more often non-specific repolarisation abnormalities at rest. Supraventricular tachycardias, such as AV nodal reentrant tachycardia, are twice as frequent in women compared with men. Atrial fibrillation, however, has a 1.5-fold higher prevalence in men. The triggers for idiopathic right ventricular outflow tract tachycardia (VT) initiation are gender specific, i.e. hormonal changes play an important role in the occurrence of these VTs in women. There are clear-cut gender differences in acquired and congenital LQTS. Brugada syndrome affects men more commonly and severely than women. Sudden cardiac death is less prevalent in women at all ages and occurs 10 years later in women than in men. This may be related to the later onset of clinically manifest coronary heart disease in women. Among patients who receive ICDs and CRT devices, women appear to be under-represented, while they may benefit even more from these novel therapies.

Sex-Based Differences in Cardiac Arrhythmias, ICD Utilisation and Cardiac Resynchronisation Therapy.

Introduction
The endoscopic laser balloon ablation system (EAS) is a relatively novel technique to perform pulmonary vein isolation (PVI) in the treatment of atrial fibrillation (AF). The present study aimed to report the results of the first 50 patients treated in the Netherlands with the EAS in terms of procedural characteristics and AF-free survival.

/pdf/first-dutch-experience-with-the-endoscopic-laser-balloon-32y4zp8x4z.pdf

First Dutch experience with the endoscopic laser balloon ablation system for the treatment of atrial fibrillation

Background The Medtronic Sprint Fidelis ICD lead is prone to failure and the rate of failure seems to be increasing The aim of this study was to investigate the rate of Sprint Fidelis lead failure, the characteristics, the mode of presentation and possible predictors of lead failure

Methods and Results The rate, characteristics and presentation of Sprint Fidelis lead failure was assessed in this single-centre survey 619 Sprint Fidelis ICD leads were implanted at our centre between December 2004 and August 2007 The mean follow-up was 32±10 (range 22–60) months; 35 patients (57%) required a lead re-implantation because of failure of the pace-sense conductor Mean duration of lead survival was 23±12 (2–46) months and the rate of failure did not stabilise during follow-up The mode of presentation was inappropriate shocks in 16 patients (457%), alarm alert in 12 patients (343%), and detection at routine follow-up in seven patients (20%) In 31 patients (89%), interrogation data revealed a sudden rise in impedance and/or frequent short VV intervals prior to lead failure and in five patients an isolated decrease of R wave (<25 mV) The interrogation data were not different from patients with shocks compared with patients without shocks The interrogation data at routine follow-up in the first three months after implant were normal and stable

Conclusion The rate of Sprint Fidelis lead failure reaches 57% at a mean follow-up duration of 32 months The rate of failure does not seem to stabilise Routine follow-up can not predict lead failure or prevent inappropriate shocks (Neth Heart J 2010;18:12-7)

P. P. H. M. Delnoy

Papers

Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally.

Incidence of lead dislodgement, malfunction and perforation during the first year following device implantation

Sex-Based Differences in Cardiac Arrhythmias, ICD Utilisation and Cardiac Resynchronisation Therapy.

First Dutch experience with the endoscopic laser balloon ablation system for the treatment of atrial fibrillation

Characteristics of Sprint Fidelis lead failure.